

03/05/98
135 U.S. PTO

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

| | | |
|---|--|---------------|
| UTILITY PATENT APPLICATION TRANSMITTAL <small>(Only for new nonprovisional applications under 37 CFR 1.53(b))</small> | Attorney Docket No. | GSF98-01 |
| | First Named Inventor or Application Identifier | |
| | Walter H. Gunzburg | |
| | Express Mail Label No. | EM012186761US |

| | | | | | |
|--|--|-----------|----------------|----------|----------------|
| APPLICATION ELEMENTS <small>See MPEP chapter 600 concerning utility patent application contents.</small> | ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231 | | | | |
| <p>1. <input checked="" type="checkbox"/> Fee Transmittal Form (Submit an original, and a duplicate for fee processing)</p> <p>2. <input checked="" type="checkbox"/> Specification [Total Pages 44] (preferred arrangement set forth below)</p> <ul style="list-style-type: none">- Descriptive title of the Invention- Cross References to Related Applications- Statement Regarding Fed sponsored R & D- Reference to Microfiche Appendix- Background of the Invention- Brief Summary of the Invention- Brief Description of the Drawings (if filed)- Detailed Description- Claim(s)- Abstract of the Disclosure <p>3. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets 10]</p> <p>4. Oath or Declaration / POA [Total Pages] a. <input type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 17 completed) [Note Box 5 below] i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</p> <p>5. <input type="checkbox"/> Incorporation By Reference (useable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.</p> <p>6. <input type="checkbox"/> Microfiche Computer Program (Appendix)</p> <p>7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. <input type="checkbox"/> Computer Readable Copy b. <input type="checkbox"/> Paper Copy (identical to computer copy) c. <input type="checkbox"/> Statement verifying identity of above copies</p> | | | | | |
| ACCOMPANYING APPLICATION PARTS | | | | | |
| <p>8. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))</p> <p>9. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney (when there is an assignee)</p> <p>10. <input type="checkbox"/> English Translation Document (if applicable)</p> <p>11. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations</p> <p>12. <input type="checkbox"/> Preliminary Amendment</p> <p>13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (2) (Should be specifically itemized)</p> <p>14. <input type="checkbox"/> Small Entity <input type="checkbox"/> Statement filed in prior application, Status still proper and desired</p> <p>15. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed)</p> <p>16. <input type="checkbox"/> Other:</p> | | | | | |
| <p>17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information: <input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No: <u>PCT / EP96/03922</u></p> | | | | | |
| 18. CORRESPONDENCE ADDRESS | | | | | |
| <p><input checked="" type="checkbox"/> Customer Number or Bar Code Label 21005 or <input type="checkbox"/> Correspondence address below (Insert Customer No. or Attach bar code label here)</p> | | | | | |
| NAME | David E. Brook, Esq. HAMILTON, BROOK, SMITH & REYNOLDS, P.C. | | | | |
| ADDRESS | Two Militia Drive | | | | |
| CITY | Lexington | STATE | MA | ZIP CODE | 02173 |
| COUNTRY | USA | TELEPHONE | (781) 861-6240 | FAX | (781) 861-9540 |

SIGNATURE

Anne J. Collins

DATE

March 5, 1998

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

| | | |
|--|------------------------|--------------------|
| FEE TRANSMITTAL FOR PATENT APPLICATIONS | Attorney Docket Number | GSF98-01 |
| | Application Number | |
| | First Named Inventor | Walter H. Gunzburg |

CLAIM CALCULATION (includes any preliminary amendment)

| CLAIMS | (1) FOR | (2) NUMBER FILED | (3) NUMBER EXTRA | (4) RATE | (5) CALCULATIONS |
|--------|--|------------------|------------------|-------------------------------|------------------|
| | TOTAL CLAIMS (37 CFR 1.16(c)) | 40 - 20 = | 20 | x \$ 22 = | \$ 440.00 |
| | INDEPENDENT CLAIMS (37 CFR 1.16(b)) | 3 - 3 = | 0 | x \$ 82 = | \$ |
| | MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(d)) | | | + \$ 270 = | \$ |
| | | | | BASIC FEE (37 CFR 1.16(a)) | \$ 790 |
| | | | | Total of above Calculations = | \$ 1,230.00 |
| | Reduction by 50% for filing by small entity (37 CFR 1.9, 1.27, 1.28) = | | | | \$ |
| | | | | TOTAL = | \$ 1,230.00 |
| | Surcharge - Fee for Late Filing of Declaration (37 C.F.R. 1.16(e)) = | | | | \$ |
| | Petition for Extension of Time Fee (37 C.F.R. 1.17) = | | | | \$ |
| | Assignment Recordation Fee = | | | | \$ |
| | | | | TOTAL = | \$ 1,230.00 |

1. Small entity status:

a. ☐ A small entity statement is enclosed.

b. ☐ A small entity statement was filed in the prior non-provisional application and such status is still proper and desired.

c. ☐ Is no longer claimed.

2. ☒ A general authorization is hereby granted to charge deposit account number 08-0380 for any fees required under 37 CFR 1.16 and 1.17 in order to maintain pendency of this application. A copy of this authorization is enclosed for accounting purposes.

3. ☒ A check is enclosed for \$ 1,230.00 ☐ Please charge \$ _____ to Deposit Account No. 08-0380.

4. ☐ Other: _____

| | | | |
|---------------------------------------|------------------------|-------------|---------------|
| Submitted by Typed or Printed Name | Anne J. Collins | Reg. Number | 40,564 |
| Signature | <i>Anne J. Collins</i> | Date | March 5, 1998 |

-1-

Date: 3-5-98 Express Mail Label No. EM012186761US

Inventors: Walter H. Günzburg, Robert M. Saller and
Brian Salmons

Attorney's Docket No.: GSF98-01

THE USE OF THE WAP OR MMTV REGULATORY SEQUENCES FOR
TARGETED EXPRESSION OF LINKED HETEROLOGOUS GENES IN HUMAN
MAMMARY CELLS, INCLUDING HUMAN MAMMARY CARCINOMA CELLS

RELATED APPLICATIONS

5 This application is a Continuation of PCT/EP96/03922,
filed September 6, 1996, which claims priority to Danish
patent application DK 0976/95 filed September 6, 1995. The
teachings of PCT/EP96/03922 and DK 0976/95 are incorporated
herein by reference in their entirety.

10 BACKGROUND OF THE INVENTION

Mammary carcinoma is the most frequent tumor in women
(Miller, A.D. and Bulbrook, R.D. *Int. J. Cancer* 37:173-177
(1986)). Up to now conventional therapy involves surgical
removal of the primary tumor followed by a chemo- or
15 radiation therapy. Depending on the tumor stage, the rate
of relapse is quite high and has a fatal outcome in most
cases.

A major problem is the elimination of all metastases and micrometastases. Both this, as well as the serious side effects for the patient caused by conventional treatment, favor the development of a gene therapy approach (for a review on gene therapy see Anderson, W.F., *Science*, 256:808-813 (1992)). A gene therapeutic approach however poses the problem of targeting the expression of the therapeutic gene to tumor cells. A control element is therefore required to ensure that the therapeutic gene is only expressed in tumor cells.

Vector constructs carrying various types of mammary gland specific regulatory elements have been tested in mice where expression of a marker gene driven by the regulatory elements in the hormonally stimulated mammary gland could be achieved (WO-A1-9607748). One regulatory element demonstrated to give rise to expression in the pregnant and lactating mouse mammary gland is a small region of the rodent WAP promoter (Kolb, A.F., et al., *J. Cell. Biochem.*, 56:245-261 (1994)). This gene is only expressed in the pregnant and lactating mammary glands of rodents and has no human homologue (Hennighausen, L., *J. Cell Biochem.*, 49:325-332 (1992)). It is therefore not predictable that this regulatory element will function at all to direct expression in human mammary cells and/or allow expression in human mammary carcinoma cells.

It was thus quite unexpected when the inventors of the present invention found that the WAP regulatory sequence is

able to direct expression of a linked heterologous gene in primary human cells, including mammary carcinoma cells.

SUMMARY OF THE INVENTION

The invention then, inter alia, comprises the
5 following, alone or in combination:

A DNA construct comprising at least one therapeutic gene under transcriptional control of the WAP or MMTV regulatory sequences for the treatment of disorders or diseases of human mammary cells, including human mammary
10 carcinoma;

a DNA construct as above wherein the regulatory sequence comprises the proximal 445 bp of the WAP promoter including the transcription initiation site.

a DNA construct as above wherein the regulatory
15 sequence contains the 320 bp XhoI/XbaI fragment of the WAP promoter region;

a DNA construct as above wherein the regulatory sequence is the U3 region of MMTV;

a DNA construct as above wherein the regulatory
20 sequence contains the 0.6 Kb PstI MMTV promoter fragment;

a DNA construct as above which is a recombinant vector selected from viral and plasmid vectors;

a recombinant vector as above wherein said viral vector is selected from RNA and DNA viral vectors and said
25 plasmid vector is selected from eucaryotic expression vectors;

a recombinant vector as above wherein said viral vector is a retroviral vector, a recombinant adenovirus vector, a recombinant adeno-associated virus vector or a recombinant herpes virus vector;

5 a recombinant vector as above wherein the retroviral vector comprises a 5'LTR region of the structure U3-R-U5; at least one coding sequence for a therapeutic gene; and a 3'LTR region comprising a completely or partially deleted U3 region wherein said deleted region has been replaced by
10 a polylinker containing the WAP or MMTV regulatory sequences followed by the R and U5 region, said therapeutic gene being under transcriptional control of the WAP or MMTV regulatory sequences;

a construct as above wherein the therapeutic gene is
15 selected from anti-tumor genes and cytokine genes for the treatment of human mammary carcinoma;

a construct as above, wherein said therapeutic gene is selected from the group consisting of genes which code for proteins such as Herpes Simplex Virus thymidine kinase,
20 cytosine deaminase, guanine phosphoribosyl transferase (gpt), cytochrome P 450, cell cycle regulatory genes which code for proteins such as SDI, tumor supressor genes which code for proteins such as p53, antiproliferation genes which codes for proteins such as melittin, cecropin or
25 cytokines such as IL-2;

a recombinant retroviral particle produced by culturing a packaging cell line harbouring a retroviral vector construct as above and one or more constructs coding

8550E0"963E050

for the proteins required for the genome of said retroviral vector to be packaged, for the treatment of disorders or diseases of human mammary cells, including human mammary carcinoma;

- 5 a retroviral provirus carrying a construct comprising at least one therapeutic gene under transcriptional control of the WAP or MMTV regulatory sequences integrated in the human genome;

- 10 a retroviral provirus as above comprising a 5'LTR region comprising a completely or partially deleted U3 region wherein said deleted region has been replaced by a polylinker containing the WAP or MMTV regulatory sequences followed by the R and U5 region; at least one coding sequence coding for a therapeutic gene; and a 3'LTR region
- 15 comprising a completely or partially deleted U3 region wherein said deleted region has been replaced by a polylinker containing the WAP or MMTV regulatory sequences followed by the R and U5 region, said therapeutic gene being under transcriptional control of the WAP or MMTV
- 20 regulatory sequences;

a cell line containing a construct as above for the treatment of disorders or diseases of human mammary cells, including human mammary carcinoma;

- 25 a cell line as above which is a packaging cell line harbouring a retroviral vector construct as above and one or more constructs coding for the proteins required for the genome of said retroviral vector to be packaged;

a human cell containing a retroviral provirus as above;

encapsulated cells comprising a core containing cells as above and a porous capsule wall surrounding said core, said porous capsule wall being permeable to the therapeutic polypeptide or the viral particles produced by said cells for the treatment of disorders or diseases of human mammary cells, including human mammary carcinoma;

encapsulated cells as above wherein said porous
10 capsule wall consists of a polyelectrolyte complex formed
from counter charged polyelectrolytes;

the use of a construct as above for the preparation of a medicament for the treatment of disorders or diseases of human mammary cells, including human mammary carcinoma;

15 the use of a recombinant viral particle as above for
the manufacture of a medicament for the treatment of
disorders or diseases of human mammary cells, including
human mammary carcinoma.

the use of cells as above for the manufacture of a
20 medicament for the treatment of a disorder or disease of
human mammary cells, including human mammary carcinoma;

a pharmaceutical composition for the treatment of disorders or diseases of human mammary cells, including human mammary carcinoma comprising a DNA construct as above
25 and a pharmaceutically acceptable carrier or diluent;

a pharmaceutical composition for the treatment of disorders or diseases of human mammary cells, including human mammary carcinoma comprising a recombinant retroviral

particle as above and a pharmaceutically acceptable carrier or diluent;

a pharmaceutical composition for the treatment of disorders or diseases of human mammary cells, including human mammary carcinoma comprising a cell line as above and a pharmaceutically acceptable carrier or diluent;

the use of the WAP or MMTV regulatory sequences for the expression of linked therapeutic genes in human mammary cells, including human mammary carcinoma cells;

10 the use as above wherein the regulatory sequence
comprises the proximal 445 bp of the WAP promoter including
the transcription initiation site;

the use as above wherein the regulatory sequence
contain the 320 bp XhoI/XbaI fragment of the WAP promoter
15 region;

the use as above wherein the regulatory sequence is the U3 region of MMTV;

the use as above wherein the regulatory sequence contains the 0.6 Kb PstI MMTV promoter fragment;

20 the use as above wherein the therapeutic gene is
selected from anti-tumor genes and cytokine genes;

the use as above, wherein said therapeutic gene is selected from the group consisting of genes which code for proteins such as Herpes Simplex Virus thymidine kinase, cytosine deaminase, guanine phosphoribosyl transferase (gpt), cytochrome P 450, cell cycle regulatory genes which code for proteins such as SDI, tumor supressor genes which code for proteins such as p53, antiproliferation genes

which codes for proteins such as melittin, cecropin or cytokines such as IL-2;

the use as above wherein the therapeutic gene under transcriptional control of the WAP or MMTV regulatory
5 sequences form part of a recombinant vector selected from viral and plasmid vectors;

the use as above wherein said viral vector is selected from RNA and DNA viral vectors and said plasmid vector is selected from eucaryotic expression vectors;

10 the use as above wherein said viral vector is a retroviral vector;

the use as above wherein the retroviral vector comprises a 5'LTR region of the structure U3-R-U5; at least one coding sequence coding for a therapeutic gene; and a 3'
15 LTR region comprising a completely or partially deleted U3 region wherein said deleted region has been replaced by a polylinker containing the WAP or MMTV regulatory sequences followed by the R and U5 region, said therapeutic gene being under transcriptional control of the WAP or MMTV
20 regulatory sequences;

a method for the treatment of human mammary carcinoma comprising administering to a human in need thereof a construct as above;

a method for the treatment of human mammary carcinoma
25 comprising administering to a human in need thereof a viral particle as above;

a method for the treatment of human mammary carcinoma comprising administering to a human in need thereof cells as above; and

a method for the treatment of human mammary carcinoma
5 comprising implanting into a human in need thereof
encapsulated cells as above either in or nearby the site of
the tumor.

The therapeutic gene is preferably selected from one or more elements of the group consisting of antitumor genes and cytokine genes.

Said therapeutic genes are preferably selected from the group consisting of genes which code for proteins such as Herpes Simplex Virus thymidine kinase, cytosine deaminase, guanine phosphoribosyl transferase (gpt),
15 cytochrome P 450, cell cycle regulatory genes such as SDI, or tumor supressor genes which codes for proteins such as p53, or antiproliferation genes which code for proteins such as melittin, cecropin or cytokines such as IL-2.

Herpes Simplex Virus thymidine kinase, cytosine
20 deaminase, guanine phosphoribosyl transferase (gpt) and
cytochrome P 450 can be used in cancer treatment in
combination with a prodrug which is converted to its toxic
form by these enzymes.

The DNA constructs according to the invention can also carry a marker gene. Said marker genes are preferably selected from the group consisting of marker genes which code for proteins such as β -galactosidase, neomycin, alcohol dehydrogenase, luciferase, puromycin, hypoxanthine

phosphoribosyl transferase (HPRT), hygromycin, secreted alkaline phosphatase and green or blue fluorescent proteins.

BRIEF DESCRIPTION OF THE DRAWINGS

- 5 Figure 1: Primers A (SEQ ID NO: 1), B (SEQ ID NO: 2),
and C (SEQ ID NO: 3) used for deletion of U3
of MLV and insertion of a SacII-Mlu
polylinker in its place.
- Figure 2: The preparation of plasmid pSmaU3del.
- 10 Figure 3: The preparation of plasmids pBAGNU3del and
pCON6.
- Figure 4: The preparation of plasmid pMMTV-BAG.
- Figure 5: Primers D (SEQ ID NO: 4) and E (SEQ ID NO:
5) used for amplification of the U3-region
15 of MMTV.
- Figure 6: Plasmid pMMTV-BAG.
- Figure 7: Primers F (SEQ ID NO: 6) and G (SEQ ID NO:
7) used for amplification of a sequence
containing the proximal 445 bp of the WAP
promoter and the first 143 bp's of human
20 growth hormone.
- Figure 8: The preparation of plasmid pWAP-BAG.
- Figure 9: Plasmid pWAP-BAG.
- Figure 10: β -Gal expression of vector constructs after
25 infection of primary human mammary gland
cells.

DETAILED DESCRIPTION OF THE INVENTION

According to the invention it has surprisingly been found that the WAP and MMTV regulatory sequences are able to direct expression of a linked heterologous gene in
5 primary human mammary cells, including human mammary carcinoma cells.

It is well known that Whey Acidic Protein (WAP) gene expression is directed to the pregnant and lactating mammary gland of rodents (Günzburg, W.H., *Mol. Endocrin.*,
10 5:123-133 (1991); Hennighausen, L., *J. Cell. Biochem.* 49:325-332 (1992)). WAP gene expression is regulated both by hormone dependent and hormone independent mechanisms. A negative regulatory element (NRE) in the WAP promoter interacts with a NRE binding factor, NBF, which is present
15 in all cells unable to express WAP (Kolb, A.F. et al., *Biochem. Biophys. Res. Commun.*, 217:1045-1052 (1995)). It appears that the region of the WAP promoter which is required for mediating the mammary gland specificity is a 320 bp XhoI/XbaI restriction fragment (-413 to -93) (Kolb, A.F. et al., *Biochem. Biophys. Res. Commun.*, 217:1045-1052
20 (1995)). In addition certain experiments indicate that binding sites for NBF is present on a 0.6 Kb PstI MMTV promoter fragment (described in Salmons, B. et al., *Virology*, 144:101-114 (1985)) and may play a role in
25 regulating the mammary gland specificity of expression displayed by MMTV (Kolb, A.F., et al., *Biochem. Biophys. Res. Commun.*, 217:1045-1052 (1995)).

The fact that the WAP and the MMTV are both derived from the rodent system may become an important safety feature because the use of human regulatory sequences in a retroviral vector may facilitate homologous recombinations
5 between the vector carried sequences and the corresponding cellular sequences and may cause genome instability.

The DNA constructs according to the invention carrying a therapeutic gene under transcriptional control of the WAP or MMTV regulatory sequences can be introduced into cells
10 using any known method for the introduction of genes into cells including by means of calcium phosphate precipitation (Graham et al., *Virology*, 52:456-467 (1973); Wigler et al., *Cell*, 777-785 (1979)), by means of electroporation (Neumann et al., *EMBO. J.*, 1:841-845 (1982)), by microinjection
15 (Graessmann et al., *Meth. Enzym.*, 101:482-492 (1983)), by means of liposomes (Straubinger et al., *Methods in Enzym.*, 101:512-527 (1983)), by means of spheroblasts (Schaffner, *Proc. Natl. Acad. Sci. USA*, 77:2163-2167 (1980)) or by other methods known to those skilled in the art.

20 The DNA constructs according to the invention carrying a therapeutic gene under transcriptional control of the WAP or MMTV regulatory sequences are preferably introduced into cells using a recombinant viral vector. Such vectors are well known in the art and include retroviral vectors,
25 recombinant adenoviruses and recombinant adeno-associated viruses (Günzburg W.H., and Salmons, B., *Mol. Med. Today*, 1:410-417 (1995)) as well as herpes virus vectors.

B659E0-965E060

In a preferred embodiment of the invention the DNA construct according to the invention is a modified retroviral vector, which is used to deliver the therapeutic gene to cells, preferably in vivo. The great advantage of a retroviral system is that retroviruses can only infect dividing cells (especially rapid dividing cells such as tumor cells) and that the virus particles can be spread in the blood stream similarly to metastasising tumor cells, which will make it possible to eliminate micrometastases long before they can be detected by conventional methods.

Retroviral vector systems consist of two components:

1. the retroviral vector itself is a modified retrovirus (vector plasmid) in which the genes encoding for the viral proteins have been replaced by therapeutic genes and/or marker genes to be transferred to the target cell. Since the replacement of the genes encoding for the viral proteins effectively cripples the virus it must be rescued by the second component in the system which provides the missing viral proteins to the modified retrovirus.

The second component is:

2. a cell line that produces large quantities of the viral proteins however lacks the ability to produce replication competent virus. This cell line is known as the packaging cell line and

consists of a cell line transfected with one or more plasmids carrying the genes enabling the modified retroviral vector to be packaged.

To generate the packaged vector, the vector plasmid is transfected into the packaging cell line. Under these conditions the modified retroviral genome including the inserted therapeutic and marker genes is transcribed from the vector plasmid and packaged into the modified retroviral particles (recombinant viral particles). This recombinant virus is then used to infect target cells in which the vector genome and any carried marker or therapeutic genes become integrated into the target cell's DNA. A cell infected with such a recombinant viral particle cannot produce new vector virus since no viral proteins are present in those cells. However the DNA of the vector carrying the therapeutic and marker genes is integrated in the cell's DNA as a provirus and can now be expressed in the infected cell.

WO-A1-9607748 describes the principle and construction
20 of a new type of retroviral vector, the ProCon-vector:

The retroviral genome consists of an RNA molecule with the structure R-U5-gag-pol-env-U3-R. During the process of reverse transcription, the U5 region is duplicated and placed at the right hand end of the generated DNA molecule, whilst the U3 region is duplicated and placed at the left hand end of the generated DNA molecule. The resulting terminal structure U3-R-U5 is called LTR (Long Terminal Repeat) and is thus identical and repeated at both ends of

the DNA structure or provirus (Varmus, H., *Science*,
240:1427-1435 (1988)). The U3 region at the left hand end
of the provirus harbors the promoter that is used to drive
expression after infection has occurred. This promoter
5 drives the synthesis of an RNA transcript initiating at the
boundary between the left hand U3 and R regions and
terminating at the boundary between the right hand R and U5
region. This RNA is packaged into retroviral particles and
transported into the target cell to be infected. In the
10 target cell the RNA genome is reverse transcribed as
described above.

In the ProCon-vector plasmid the right-hand (3') U3
region is altered, but the normal left-hand (5') U3
structure is maintained; the vector can be normally
15 transcribed into RNA utilizing the normal retroviral
promoter located within the left-hand (5') U3 region upon
its introduction into packaging cells. However the
generated RNA will only contain the altered right-hand (3')
U3 structure. In the infected target cell, after reverse
20 transcription, this altered U3 structure will be present in
both Long Terminal Repeat at either end of the retroviral
structure.

If the altered region carries a polylinker instead of
the U3 region then any promoter, including those directing
25 tissue specific expression such as the WAP regulatory
sequences can easily be inserted. This promoter can then
be utilized exclusively in the target cell for expression
of linked genes carried by the retroviral vector.

Additionally DNA segments homologous to one or more cellular sequences can be inserted into the polylinker for the purposes of gene targeting by homologous recombination.

The retroviral vectors of the invention need not be of the ProCon type, but can be any conventional retroviral vector carrying therapeutic genes under transcriptional control of the WAP or MMTV regulatory sequences.

Such vectors include Self-Inactivating-Vectors (SIN) in which retroviral promoters are functionally inactivated in the target cell (WO-A1-94/29437). Further modifications of these vectors include the insertion of promoter gene cassettes within the LTR region to create double copy vectors (WO-A1-89/11539). In both of these vectors the heterologous promoters inserted either in the body of the vector, or in the LTR region are directly linked to the therapeutic gene.

The vector of the invention is preferably a retroviral vector wherein the WAP or MMTV promoters are used as internal promoters, i.e., *LTR-neo-WAP-tk-LTR*, but most preferably the retroviral vector of the invention is of the ProCon type.

The retroviral vector is based preferably either on a BAG vector (Price, J., et al., *Proc. Natl. Acad. Sci. USA*, 84:156-160 (1987)) or an LXS vector (Miller A.D. and Rosman, G.J., *Biotechniques* 7:980-990 (1989)), or derivatives thereof.

Retroviral particles can be made by introducing a viral vector construct into a packaging cell which contain

the elements lacking in the vector construct (e.g. gag, pol, and env) which are necessary for the production of infectious retroviruses.

The packaging cell line can be selected from an
5 element of the group consisting of psi-2 (Mann, M. et al.,
Cell, 33:153-159 (1983)), psi-Crip (Danos, O. and Mulligan,
R.C., *Proc. Natl. Acad. Sci. USA*, 85:6460-6464 (1988)),
psi-AM (Cone R.D. and Mulligan, R.C., *Proc. Natl. Acad.*
Sci. USA, 81:6349-6353 (1984)), GP+E-86 (Markowitz, D. et
10 al., *J. Virol.*, 62:1120-1124 (1988a), PA317 (Miller A.D.
and Buttimore, C., *Mol. Cell. Biol.*, 6:2895-2902 (1986)),
GP+envAM-12 (Markowitz, D. et al., *Virology*, 167:400-406
(1988b), Bosc 23, Bing (Pear, W.S. et al., *Proc. Natl.*
Acad. Sci. USA, 90:8392-8396 (1993)) or FLYA13, FLYRD 18
15 (Casset F.L. et al., *J. Virol.*, 69:7430-7436 (1995)) or of
any of these transfected with recombinant constructs
allowing expression of surface proteins from other
enveloped viruses. Such pseudotyped retroviral particles
are described in PCT/EP96/01348.

20 In particular preferred embodiment, the packaging cell
line is made from human cells, e.g. HT10808 cells (WO-A1-
9621014), 293 (Graham et al., *J. Gen. Virol.*, 36:59 (1977))
or mink cell lines thereby allowing production of
recombinant retroviruses that are capable of surviving
25 inactivation by human serum.

According to the invention the term "polylinker" is
used for a short stretch of artificially synthesized DNA

-18-

which carries unique restriction sites allowing the easy insertion of any promoter or DNA segment.

The term "heterologous" is used for any combination of DNA sequences that is not normally found intimately
5 associated in nature.

PRESERVATION AND ADMINISTRATION OF VIRAL PARTICLES

Recombinant retrovirus which has been purified or concentrated may be preserved by first adding a sufficient amount of formulation buffer to the media containing the
10 recombinant retrovirus, in order to form an aqueous suspension. The formulation buffer is an aqueous solution that contains a saccharide, a high molecular weight structural additive, and a buffering component in water. The aqueous solution may also contain one or more amino
15 acids.

The recombinant retrovirus can also be preserved in a purified form. More specifically, prior to the addition of the formulation buffer, the crude recombinant retrovirus described above may be clarified by passing it through a
20 filter, and then concentrated, such as by a cross flow concentrating system (Filtron Technology Corp., Northborough, MA). Within one embodiment, DNase is added to the concentrate to digest exogenous DNA. The digest is then diafiltrated to remove excess media components and
25 establish the recombinant retrovirus in a more desirable buffered solution. The diafiltrate is then passed over a Sephadex S-500 gel column and a purified recombinant

retrovirus is eluted. A sufficient amount of formulation buffer is added to this eluate to reach a desired final concentration of the constituents and to minimally dilute the recombinant retrovirus, and the aqueous suspension is then stored, preferably at -70°C or immediately dried. As noted above, the formulation buffer is an aqueous solution that contains a saccharide, a high molecular weight structural additive, and a buffering component in water. The aqueous solution may also contain one or more amino acids.

The crude recombinant retrovirus can also be purified by ion exchange column chromatography. In general, the crude recombinant retrovirus is clarified by passing it through a filter, and the filtrate loaded onto a column containing a highly sulfonated cellulose matrix. The recombinant retrovirus is eluted from the column in purified form by using a high salt buffer. The high salt buffer is then exchanged for a more desirable buffer by passing the eluate over a molecular exclusion column. A sufficient amount of formulation buffer is then added, as discussed above, to the purified recombinant retrovirus and the aqueous suspension is either dried immediately or stored, preferably at -70°C .

The aqueous suspension in crude or purified form can be dried by lyophilisation or evaporation at ambient temperature. Specifically, lyophilisation involves the steps of cooling the aqueous suspension below the glass transition temperature or below the eutectic point

5

drying.

10

structural support in the lyophilised or dried state.

20

25

the cooled aqueous suspension and while in the lyophilised state.

The buffering component acts to buffer the solution by maintaining a relatively constant pH. A variety of buffers
5 may be used, depending on the pH range desired, preferably between 7.0 and 7.8.

Aqueous solutions for the formulation of recombinant retroviruses are described in detail in WO-A2-96121014.

In addition, it is preferable that the aqueous
10 solution contain a neutral salt which is used to adjust the final formulated recombinant retrovirus to an appropriate iso-osmotic salt concentration.

Lyophilized or dehydrated retroviruses may be reconstituted using a variety of substances, but are
15 preferably reconstituted using water. In certain instances, dilute salt solutions which bring the final formulation to isotonicity may also be used. In addition, it may be advantageous to use aqueous solutions containing components known to enhance the activity of the
20 reconstituted retrovirus. Such components include cytokines, such as IL-2, polycations, such as protamine sulfate, or other components which enhance the transduction efficiency of the reconstituted retrovirus. Lyophilized or dehydrated recombinant retrovirus may be reconstituted with
25 any convenient volume of water or the reconstituting agents that allow substantial, and preferably total solubilization of the lyophilized or dehydrated sample.

863020-3636050

Recombinant retroviral particles may be administered to a wide variety of locations including, for example, into sites such as an organ or to a site of a tumor. Within other embodiments, the recombinant retrovirus may be administered orally, intravenously, buccal/sublingual, intraperitoneally, or subcutaneously. The daily dosage depends upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and further the preference and experience of the physician in charge.

The routes of administration described herein may be accomplished simply by direct administration using a needle, catheter or related device. In particular, within certain embodiments of the invention, one or more dosages may be administered directly.

In another embodiment of the invention a cell line according to the invention producing either a therapeutic polypeptide or viral particles carrying a therapeutic gene under the transcriptional control of the WAP or MMTV regulatory sequences is encapsulated in a porous membrane which is permeable to the therapeutic polypeptide or viral particles produced (Stange, J. et al., *Biomat. Art. Cells & Immob., Biotech.*, 21(3):343-352 (1993); Dautzenberg, H., et al., *Biomat. Art. Cells & Immob., Biotech.*, 21:(3):399-405 (1993); Merten O.W. et al., *Cytotechnology*, 121-130 (1991) and UK Patent Application 2 135 954)).

5

15

20

25

in PBS. Capsule formation occurs within milliseconds and the capsules containing cells are kept in the precipitation bath for 30 seconds to 5 minutes and then washed. The rapidity of this method ensures that the cells are not
5 unduly stressed during the whole procedure (Stange, J. et al., *Biomat. Art. Cells & Immob., Biotech* 21(3):343-352 (1993)).

The encapsulated cells can be cultivated in a normal cell culture medium (the nature of which depends on the
10 encapsulated cells) at standard conditions of humidity, temperature and CO₂ concentration. During this culture period production of therapeutic polypeptides and viral particles from the capsules into the cell culture medium can be demonstrated. Production of viral particles can be
15 demonstrated using for RT-PCR technology or by transfer of cell free (0.45 μ m filtered) supernatant to target cells followed by the demonstration of viral infection by assay for the activity of marker proteins encoded by genes carried by the viral vector construct contained within the
20 viral particle. If the marker gene carried by the viral vector is a gene conferring resistance to a specific compound upon the target cell or the product of which is easily assayed on a cell to cell basis e.g. green or blue fluorescent protein, the titre of virus produced by the
25 system can be ascertained.

After a suitable period in culture (normally not less than 1 hour and not exceeding 30 days), the cell containing capsules can be surgically implanted either directly, or by

8650E0"965E060

injection using a syringe into various areas of the body including the breast.

The following examples will illustrate the invention further. The example is however in no way intended to
5 limit the scope of the present invention as obvious modifications will be apparent, and still other modifications and substitutions will be apparent to anyone skilled in the art.

The recombinant DNA methods employed in practicing the
10 present invention are standard procedures, well known to those skilled in the art, and described in detail, for example, in "Molecular Cloning" (Sambrook, J., et al., *Molecular Cloning*, Cold Spring Harbor Laboratory Press, New York, USA (1989)) and in "A Practical Guide to Molecular
15 Cloning" (Perbal, B., *A Practical Guide to Molecular Cloning*, John Wiley & Sons (1994)).

EXAMPLE 1

DELETION OF THE U3 REGION AND INSERTION OF A POLYLINKER

In the murine leukemia virus (MLV) retroviral vector
20 known as BAG (Price, J., et al., *Proc. Natl. Acad. Sci. USA*, 84:156-160 (1987)) the β -galactosidase gene is driven by the promiscuous (i.e. non-tissue specific) MLV promoter in the U3 region of the LTR. According to the present invention a derivative of the BAG vector has been
25 constructed in which the MLV promoter (U3) located within the 3'LTR except the inverted repeat has been deleted by PCR and replaced by a polylinker. The BAG vector lacking

the U3 is expressed from the MLV promoter (U3) within the 5'LTR when introduced into a packaging cell line. As a result of the rearrangements occurring in the retroviral genome during its life cycle, following infection of its target cell, the polylinker will be duplicated at both ends of the retroviral genome as described in WO-A1-9607748. Thereby a retroviral vector can be constructed in which the expression of the β -galactosidase gene of BAG will be controlled by any heterologous promoter inserted into the polylinker.

As a template for PCR we used pBAGN a plasmid carrying a derivative of the BAG construct carrying only one LTR, created by an NheI digest of the original pBAG followed by a self-ligation of the 7018bp fragment.

The 3' end of primer A is complementary to the R-region of the LTR (Figure 1). The 5'-extension contains an artificial (art.) polylinker and an artificial inverted repeat (IR(art.)). Primer B is complementary to the U5 region of the LTR (Figure 1). After 35 cycles of annealing at 47°C and extension at 60°C, a 140bp product was obtained, which was used as a template for the second PCR. In this reaction a ClaI site and an artificial (+)PBS was added 5' of the IR-region using primer C (Figure 1) in combination with primer B. Annealing was carried out at 53°C and extension at 72°C. After 35 cycles a 163bp product was obtained, which was digested with ClaI and SmaI and ligated to a 2722bp ClaI/SmaI fragment of pSmaI (Figure 2). The resulting plasmid pSmaIU3del (2792bp) was

linearized by a SmaI digest and ligated to a 3677bp SmaI
fragment of pBAGN (Figure 3) to give the plasmid pBAGNU3del
(6469bp). Deletion of the U3 region was confirmed by
sequencing from the ClaI-site into the U5-region using
5 pSmaIU3del as template.

A ClaI/SpeI (322bp) fragment containing the U3 deleted
LTR was ligated to a ClaI/NheI fragment of pBAGNB (created
by self ligation of a 3946pb fragment of pBAGN) to give the
plasmid pCON6 (4097bp) (Figure 3). This plasmid carrying a
10 full U3-minus retroviral vector was used as a basis for
further cloning.

According to the principle set forth above the
following specific promoters have been inserted into the
polylinker region or the modified BAG vector.

15 EXAMPLE 2

Cloning of pMMTVgal

The Mouse Mammary Tumor Virus (MMTV) U3-Region (mtv-2)
without the inverted repeats includes a region that confers
responsiveness to glucocorticoid hormones and a region
20 containing an element that directs expression to the
mammary gland.

The U3 region of MMTV was amplified by PCR using the
plasmid pBG102 (a plasmid containing the 3' LTR from mtv 2)
as template with primers D and E.

25 The 3' end of primer D is complementary to the 5' end
of the MMTV U3 region and carries a SacII site in its 5'
extension (Figure 5). The 3' end of primer E is

complementary to the 3' end of the MMTV U3 region and has a MluI site in its 5' extension (Figure 5).

After 35 cycles of annealing at 49°C and extension at 72°C, a 1229bp product was obtained, digested with SacII and MluI and ligated to the SacII/MluI digested vector pCON6. The resulting plasmid p125.6 (5305bp) (Figure 4) was digested with XbaI and HindIII and the 4187 bp fragment ligated to the 4190bp fragment of pBAGN containing the β -galactosidase gene to give the plasmid pMMTV-BAG (8377bp) (Figure 4) in which the β -galactosidase gene is under the transcriptional control of the MLV promoter after transfection, and under the MMTV promoter after infection (Figure 6).

EXAMPLE 3

Cloning of the Whey Acidic Protein (WAP) promoter region encompassing the proximal 445 bp of the WAP promoter including the transcription initiation site.

A plasmid, pWAPBAG containing the β -galactosidase gene under transcriptional control of the proximal 445 bp's of the WAP promoter was prepared by amplification of a sequence comprising the proximal 445 bp's of the WAP promoter and the first 143 bp's of the human growth hormone (HGH). The sequences were amplified from pWAP2-HGH (Günzburg W.H. et al., *Molecular Endocrinology*, 5:123-133 (1991)) by PCR using primers F and G. (Figure 7). Both primers carried SacII and MluI recognition sites as terminal sequences. The amplified 606 bp product and pCON6

were digested with SacI and MluI and the 4094 bp fragment of the vector as well as the PCR product was ligated together to create pWAP.6. The β -galactosidase (β -gal) gene of E.coli was cloned into the resulting vector pWAP.6 (4687 bp) (Figure 8); pWAP.6 as well as pBAGN were digested with BamHI and the linearized vector fragment as well as the 3072 bp β -gal fragment of pBAGN were ligated together. The resulting plasmid was pWAPBAG (Figure 9), which is a ProCon vector in which the 3' 445 bp's containing the WAP-NRE, as well as the 5' 143 bp's of the HGH coding sequence, were inserted in place of the U3 region in the 3' LTR.

EXAMPLE 4

The control of the B-galactosidase gene expression under the transcriptional control of the WAP and MMTV promoters inserted into the polylinker has been validated by infection studies using the constructed MMTV and WAP retroviral vectors to infect various cells.

To produce retroviral vector particles, the MMTV and WAP ProCon vectors have been transfected into the packaging cell line PA317 (Miller, A.B. and Buttimore, C., *Mol. Cell. Biol.*, 6:2895-2902 (1986)). After selection for neomycin resistance, which is encoded by the vector, stable populations and clones of recombinant ProCon virus producing cells were obtained. Virus containing supernatant from these populations was used to infect explanted normal primary human mammary tissue obtained from reduction mammaplasties. Since it is known that the WAP

and MMTV promoters are responsive to pregnancy hormones, the tissue was cultivated in the presence of 10^{-6} M dexamethasone, insulin ($1\mu\text{g/ml}$), EGF (5ng/ml) and Cortisol (0.1 g/ml). The expression of the marker gene was
5 determined by a quantitative β -gal assay which is based on the detection of β -galactosidase activity by chemiluminescence.

β -gal assay:

The levels of β -galactosidase activity were assayed
10 using the Tropix kit according to the manufacturers' instructions. The cells were trypsinised, washed twice with PBS and lysed. The protein concentration was determined by a modified Lowry (BioRad DC protein assay).
5 and $10\text{ }\mu\text{g}$ of protein was used for the β -gal assay. The
15 kit uses a substrate that is cleaved by the enzyme and thus the amount of enzyme activity is proportional to the amount of light produced. Expression was quantified by measuring chemiluminescence in a Berthold AutoLumat 953 (EG+G Berthold).

20 Detection of infected cells by histochemical staining was performed as outlined previously ([Cepko, 1989]). Briefly, the cells were washed with chilled PBS and then fixed with a 2% paraformaldehyde solution for 20 mins. After extensive washing with PBS, the cells were incubated
25 in a solution containing the substrate X-gal ($20\text{ mM K}_3\text{Fe(CN)}_6$, $20\text{mM K}_4\text{Fe(CN)}_6 \cdot 3\text{H}_2\text{O}$, 2mM MgCl_2 and 1 mg/ml X-gal) for at least 2 hours at 37°C .

In all the experiments the original, non-tissue specific BAG-vector was used as a positive control. After infection of normal primary human mammary gland cells with BAG, WAPBAG and MMTVBAG, samples showed β -galactosidase expression (Figure 10) in three independent experiments. It has thus been demonstrated for the first time that the WAP regulatory elements as well as the MMTV-U3 region can drive the expression of a gene within a MLV retroviral vector in primary human mammary gland cells.

10 EXAMPLE 5

Cytochrome P450 catalyses the hydroxylation of the commonly used cancer prodrugs cyclophosphamide (CPA) and ifosfamide to their active toxic forms. Normally the expression of the patient's endogenous cytochrome P450 gene is limited to the liver, and anti-tumor effects of systemically applied CPA's depend upon the subsequent systemic distribution of toxic drug metabolites from the liver. This has led to toxicity problems since the activated drug not only affects the tumor but also affects other normal patient tissues such as bone marrow and kidney.

A therapeutic approach, where the cytochrome P450 gene is selectively introduced directly into tumor cells, and overexpressed in these cells, would circumvent this problem. Toxic metabolites produced from the transduced tumor cells affect surrounding non-transduced tumor cells in a concentration gradient dependent manner. An

additional advantage of the cytochrome P-450/CPA system is the lack of dependency upon cell replication for cytotoxic effects on the surrounding cells. This is because one of the active metabolites generated causes interstrand
5 crosslinks regardless of the cell cycle phase. Later on, during DNA synthesis, these interstrand crosslinks result in cell death.

Construction of a retroviral vector carrying the rat cytochrome P450 gene under control of the WAP regulatory
10 sequence:

To yield the rat cytochrome P450 2B1 gene, cells of the rat hepatoma cell line HTC were lysed with solution D (4M guanidium thiocyanate, 25mM sodium citrate pH7, 0.5%N-laurylsarcosine sodium, 0.1M 2-mercaptoethanol) and total
15 RNA extracted by adding 1/15 volume of 3M sodium acetate, in the same volume of watersaturated phenol and 1/5 volume of chloroform/isoamylalcohol (49:1) were added and the whole mixture mixed vigorously. After 15 minutes on ice the extract was centrifuged 20 minutes as 4°C and 10,000g.
20 The RNA in the Aqueous phase was precipitated with one volume of isopropanol for 30 minutes at 20°C and centrifuged at 10,000g at 4°C. The pellet was washed in 70% ethanol and left at room temperature for 15 minutes. After 5 minute centrifugation at 4°C and 10,000g the pellet
25 was dried in a vacuum dryer and redissolved in 0.5% SDS solution.

The extracted RNA is reverse transcribed using the protocol for cDNA synthesis (Pharmacia). The resulting

355020" 9655E050

cDNA is used as template for PCR. The primers are designed so that they contained a BamHI restriction site (underlined) in the lefthand primer (e.g.

5 'AAGCCGGATCCCTGGAGAGCATGCAC-3' (SEQ ID NO: 8)) and a BamHI
5 site (underlined) in the righthand primer (e.g.
5 'CGATTAGGATCCCTGCCTCA-3' (SEQ ID NO: 9)). Both primers
have additional bases at the 5'-end for higher efficiency
of cleavage by the relevant restriction enzyme. The 1562
bp-product is digested with BamHI and the fragment obtained
10 is containing the gene for P450 is ligated into the BamHI
digested plasmid pWAP.6 (example 3).

One day before lipofection 3×10^5 retroviral packaging
cells are seeded into 6cm petri or culture dishes. On the
day of infection $2 \mu\text{g}$ of the vector encoding cytochrome P450
15 under transcriptional control of the WAP regulatory
sequence are mixed with $100 \mu\text{l}$ serum free media. In
parallel $15 \mu\text{l}$ of Lipofectamine (Gibco BRL) is mixed with
 $100 \mu\text{l}$ serumfree media. The plasmid containing solution is
added to the Lipofectamine-mix and incubated for 45
20 minutes. After 35 minutes the cells are washed once with
 2ml serum free media. $800 \mu\text{l}$ of serum free media were added
to the lipofection-mix and the resulting 1ml is put onto
the prepared cells. After 6 hours 1ml Dulbecco's modified
Eagles medium containing 10% FCS is added. The next day
25 the cells are trypsinized and 1:10 diluted and seeded on a
 100mm dish. After 24h the media is replaced with medium
containing the neomycin analog G418. Single cell clones or

cell populations are isolated and analysed for expression of cytochrome P450.

ENCAPSULATION OF CELLS AND IMPLANTATION OF ENCAPSULATED CELLS

5 The retroviral vector producing packaging cells are suspending in 1ml of 0.5-50%, but preferably 2-5%, anionic polymer (e.g. sodium cellulose sulphate) solution which also contains 5% fetal calf serum. This suspension is then dropped by a dispensing system (e.g. A-jet system or
10 piezoelectric system) into a precipitation bath containing a stirred 0.5%-50% polymeric polycation (e.g. polydimethyldiallylammonium). The capsule formation occurs within milliseconds and the capsules containing cells are kept in the precipitation bath for 30 seconds to 5 minutes
15 and then washed. The rapidity of this method ensures that the cells are not unduly stressed during the whole procedure. (Stange, L. et al., *Biomat. Art. Cells & Immob. Biotech.*, 21(3):343-352 (1993)).

20 The capsules producing viral particles are implanted in or around the mammary tumor in capsules thereby ensuring continuous release of virus.

25 Alternatively, the virus could be introduced by multiple direct injections into the mammary tumor. Systemic or local administration of cyclophosphamide or ifosfamide will result in local conversion of these compounds to their toxic forms leading to ablation of tumor cells.

CLAIMS

What is claimed is:

1. A DNA construct comprising at least one therapeutic gene under transcriptional control of the WAP or MMTV regulatory sequences for the treatment of disorders or diseases of human mammary cells, including human mammary carcinoma.
2. A DNA construct according to claim 1 wherein the regulatory sequence comprises the proximal 445 bp of the WAP promoter including the transcription initiation site.
3. A DNA construct according to claims 1 wherein the regulatory sequence contains the 320 bp XhoI/XbaI fragment of the WAP promoter region.
4. A DNA construct according to claim 1 wherein the regulatory sequence is the U3 region of MMTV.
5. A DNA construct according to claim 1 wherein the regulatory sequence contain the 0.6 Kb PstI MMTV promoter fragment.

6. A DNA construct according to claim 1 which is a recombinant vector selected from viral and plasmid vectors.
7. A recombinant vector according to claim 6 wherein said
5 viral vector is selected from RNA and DNA viral vectors and said plasmid vector is selected from eucaryotic expression vectors.
8. A recombinant vector according to claim 7 wherein said
10 viral vector is a retroviral vector, a recombinant adenovirus vector, a recombinant adeno-associated virus vector or a recombinant herpes virus vector.
9. A recombinant vector according to claim 8 wherein the
15 retroviral vector comprises a 5'LTR region of the structure U3-R-U5; at least one coding sequence coding for a therapeutic gene; and a 3' LTR region comprising a completely or partially deleted U3 region wherein said deleted region has been replaced by a polylinker containing the WAP or MMTV regulatory sequences followed by the R and U5 region, said therapeutic gene
20 being under transcriptional control of the WAP or MMTV regulatory sequences.

8650E0"965E050

10. A construct according to claim 1 wherein the therapeutic gene is selected from anti-tumor genes and cytokine genes for the treatment of human mammary carcinoma.
- 5 11. A construct according to claim 10, wherein said therapeutic gene is selected from the group consisting of genes which code for proteins such as Herpes Simplex Virus thymidine kinase, cytosine deaminase, guanine phosphoribosyl transferase (gpt), cytochrome P
10 450, cell cycle regulatory genes which code for proteins such as SDI, tumor supressor genes which code for proteins such as p53, antiproliferation genes which codes for proteins such as melittin, cecropin or cytokines such as IL-2.
- 15 12. A recombinant retroviral particle produced by culturing a packaging cell line harbouring a retroviral vector construct according to claim 8 and one or more constructs coding for the proteins required for the genome of said retroviral vector to
20 be packaged, for the treatment of disorders or diseases of human mammary cells, including human mammary carcinoma.

RECEIVED 950606

22. The use of cells according to claim 15 for the manufacture of a medicament for the treatment of a disorder or disease of human mammary cells, including human mammary carcinoma.
- 5 23. A pharmaceutical composition for the treatment of disorders or diseases of human mammary cells, including human mammary carcinoma comprising a DNA construct according to claim 1 and a pharmaceutically acceptable carrier or diluent.
- 10 24. A pharmaceutical composition for the treatment of disorders or diseases of human mammary cells, including human mammary carcinoma comprising a recombinant retroviral particle according to claim 12 and a pharmaceutically acceptable carrier or diluent.
- 15 25. A pharmaceutical composition for the treatment of disorders or diseases of human mammary cells, including human mammary carcinoma comprising a cell line according to claim 15 and a pharmaceutically acceptable carrier or diluent.
- 20 26. The use of the WAP or MMTV regulatory sequences for the expression of linked therapeutic genes in human mammary cells, including human mammary carcinoma cells.

365020 365020 365020

27. The use according to claim 26 wherein the regulatory sequence comprises the proximal 445 bp of the WAP promoter including the transcription initiation site.
28. The use according to claim 26 wherein the regulatory
5 sequence contains the 320 bp XhoI/XbaI fragment of the WAP promoter region.
29. The use according to claim 26 wherein the regulatory sequence is the U3 region of MMTV.
30. The use according to claim 26 wherein the regulatory
10 sequence contain the 0.6 Kb PstI MMTV promoter fragment.
31. The use according to claim 26 wherein the therapeutic gene is selected from anti-tumor genes and cytokine genes.
- 15 32. The use according to claim 31, wherein said therapeutic gene is selected from the group consisting of genes which code for proteins such as Herpes Simplex Virus thymidine kinase, cytosine deaminase, guanine phosphoribosyl transferase (gpt), cytochrome P
20 450, cell cycle regulatory genes which code for proteins such as SDI, tumor supressor genes which code for proteins such as p53, antiproliferation genes

which codes for proteins such as melittin, cecropin or cytokines such as IL-2.

33. The use according to claim 26 wherein the therapeutic gene under transcriptional control of the WAP or MMTV regulatory sequences form part of a recombinant vector selected from viral and plasmid vectors.
34. The use according to claim 33 wherein said viral vector is selected from RNA and DNA viral vectors and said plasmid vector is selected from eucaryotic expression vectors.
35. The use according to claim 34 wherein said viral vector is a retroviral vector.
36. The use according to claim 35 wherein the retroviral vector comprises a 5'LTR region of the structure U3-R-U5; at least one coding sequence coding for a therapeutic gene; and a 3' LTR region comprising a completely or partially deleted U3 region wherein said deleted region has been replaced by a polylinker containing the WAP or MMTV regulatory sequences followed by the R and U5 region, said therapeutic gene being under transcriptional control of the WAP or MMTV regulatory sequences.

37. A method for the treatment of human mammary carcinoma comprising administering to a human in need thereof a construct according to claim 1.
38. A method for the treatment of human mammary carcinoma comprising administering to a human in need thereof a viral particle according to claim 12.
39. A method for the treatment of human mammary carcinoma comprising administering to a human in need thereof cells according to claim 15.
40. A method for the treatment of human mammary carcinoma comprising implanting into a human in need thereof encapsulated cells according to claim 19 either in or nearby the site of the tumor.

THE USE OF THE WAP OR MMTV REGULATORY SEQUENCES FOR
TARGETED EXPRESSION OF LINKED HETEROLOGOUS GENES IN HUMAN
MAMMARY CELLS, INCLUDING HUMAN MAMMARY CARCINOMA CELLS

ABSTRACT OF THE DISCLOSURE

5 The present invention relates to the use of the rodent
WAP (Whey Acidic Protein) and the MMTV (Mouse Mammary Tumor
Virus) regulatory sequences for targeted expression of
linked heterologous genes, in particular therapeutic genes
in human mammary cells, including human mammary carcinoma
10 cells.

3650E0"0639E060




Figure 1




Figure 2

The diagram illustrates the construction of the pCON6 vector through a series of cloning steps:

- pSmaU3del (2792 bps)**: A circular plasmid with a pBRori origin and an SV40ori origin. It is digested with SmaI (2790) and ClaI (2721) to create a 3946 bp fragment.
- pBAGN (7018 bps)**: A circular plasmid with a pBRori origin and an SV40ori origin. It is digested with BamHI to create a 3946 bp fragment.
- pBAGNB (3946 bps)**: The 3946 bp fragment from pBAGN is self-ligated to form pBAGNB.
- pBAGNU3del (6469 bps)**: pBAGNB is digested with SmaI and ClaI to create a 4097 bp fragment.
- pCON6 (4097 bps)**: The 4097 bp fragment is self-ligated to form the final pCON6 vector. The pCON6 vector contains the (+)PBS IR PL R US region, pBRori, SV40ori, and various restriction sites (SmaI, ClaI, XbaI, SpeI, HindIII).

Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9

**β -Gal Expression of Vector
Constructs after Infection of 1°
Human Mammary Gland Cells**




Figure 10